Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

NCT03199053 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Dapagliflozin
DRUG: Saxagliptin
DRUG: Placebo

Sponsor

AstraZeneca